LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 637

Search options

  1. Article ; Online: DNA and protein HIV vaccines: how should we mix it?

    Levy, Yves

    The lancet. HIV

    2024  Volume 11, Issue 5, Page(s) e274–e275

    MeSH term(s) Humans ; AIDS Vaccines/immunology ; HIV Infections/prevention & control ; Vaccines, DNA ; HIV-1/immunology
    Chemical Substances AIDS Vaccines ; Vaccines, DNA
    Language English
    Publishing date 2024-02-09
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(24)00092-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: L'infection par le VIH

    Lévy, Yves

    (Médecine thérapeutique ; 5, Hors sér. 1)

    1999  

    Author's details coord. par Yves Lévy
    Series title Médecine thérapeutique ; 5, Hors sér. 1
    Collection
    Language French
    Size 112 S. : Ill., graph. Darst.
    Publisher Libbey Eurotext
    Publishing place Montrouge
    Publishing country France
    Document type Book
    HBZ-ID HT010299498
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Article ; Online: Genomic medicine 2025: France in the race for precision medicine.

    Lévy, Yves

    Lancet (London, England)

    2016  Volume 388, Issue 10062, Page(s) 2872

    MeSH term(s) Forecasting ; France ; Genomics/trends ; Health Planning ; Humans ; Precision Medicine/trends
    Language English
    Publishing date 2016--10
    Publishing country England
    Document type Letter
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(16)32467-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Gene and Cell Therapies: Inserm at the Heart of Biomedical Revolutions.

    Lévy, Yves

    Human gene therapy

    2016  Volume 27, Issue 2, Page(s) 98–99

    MeSH term(s) Cell- and Tissue-Based Therapy/methods ; Cell- and Tissue-Based Therapy/trends ; Clinical Trials as Topic ; France ; Friedreich Ataxia/genetics ; Friedreich Ataxia/pathology ; Friedreich Ataxia/therapy ; Genetic Therapy/methods ; Genetic Therapy/trends ; Heart Failure/genetics ; Heart Failure/pathology ; Heart Failure/therapy ; Human Embryonic Stem Cells/cytology ; Human Embryonic Stem Cells/physiology ; Human Embryonic Stem Cells/transplantation ; Humans ; Macular Degeneration/genetics ; Macular Degeneration/pathology ; Macular Degeneration/therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Neoplasms/therapy ; Parkinson Disease/genetics ; Parkinson Disease/pathology ; Parkinson Disease/therapy ; Retinitis Pigmentosa/genetics ; Retinitis Pigmentosa/pathology ; Retinitis Pigmentosa/therapy ; Translational Medical Research/trends
    Language English
    Publishing date 2016-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1028152-6
    ISSN 1557-7422 ; 1043-0342
    ISSN (online) 1557-7422
    ISSN 1043-0342
    DOI 10.1089/hum.2016.29021.yle
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book ; Online: Élire domicile : La construction sociale des choix résidentiels

    Authier, Jean-Yves / Bonvalet, Catherine / Lévy, Jean-Pierre

    2010  

    Abstract: Où décide-t-on dhabiter ? Comment sopère le choix du logement, du quartier, du statut doccupation ? À ces questions de base répondent ici des chercheurs de différentes disciplines (sociologie, géographie, économie, démographie ... ), travaillant dans des ... ...

    Abstract Où décide-t-on dhabiter ? Comment sopère le choix du logement, du quartier, du statut doccupation ? À ces questions de base répondent ici des chercheurs de différentes disciplines (sociologie, géographie, économie, démographie...), travaillant dans des contextes nationaux divers. Les réponses apportées, tout en soulignant le poids fort des contraintes (économiques, sociales, contextuelles...), montrent lexistence doptions mouvantes, incertaines, justifiant une analyse approfondie
    Keywords Social sciences (General)
    Size 1 electronic resource ( pages)
    Publisher Presses universitaires de Lyon
    Document type Book ; Online
    Note French ; Open Access
    HBZ-ID HT020320659
    ISBN 9782729711092 ; 2729711090
    DOI 10.4000/books.pul.4821
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  6. Article ; Online: Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study.

    Bensmail, Djamel / Karam, Pierre / Forestier, Anne / Loze, Jean-Yves / Lévy, Jonathan

    Toxins

    2023  Volume 15, Issue 4

    Abstract: There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients ... ...

    Abstract There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (
    MeSH term(s) Humans ; Retrospective Studies ; Urinary Bladder, Neurogenic/drug therapy ; Multiple Sclerosis/drug therapy ; Treatment Outcome ; Botulinum Toxins, Type A/therapeutic use ; Urinary Bladder, Overactive/drug therapy ; Muscle Spasticity/drug therapy ; Neuromuscular Agents/therapeutic use ; Urodynamics
    Chemical Substances Botulinum Toxins, Type A (EC 3.4.24.69) ; Neuromuscular Agents
    Language English
    Publishing date 2023-04-12
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2518395-3
    ISSN 2072-6651 ; 2072-6651
    ISSN (online) 2072-6651
    ISSN 2072-6651
    DOI 10.3390/toxins15040280
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France.

    Levy, Jonathan / Karam, Pierre / Forestier, Anne / Loze, Jean-Yves / Bensmail, Djamel

    Frontiers in neurology

    2023  Volume 14, Page(s) 1245228

    Abstract: Background: Current guidelines recommend intramuscular botulinum toxin type A (BoNT-A) injection as first-line treatment for spasticity, a frequent and impairing feature of various central nervous system (CNS) lesions such as stroke. Patients with ... ...

    Abstract Background: Current guidelines recommend intramuscular botulinum toxin type A (BoNT-A) injection as first-line treatment for spasticity, a frequent and impairing feature of various central nervous system (CNS) lesions such as stroke. Patients with spasticity commonly require BoNT-A injections once every 3 to 4 months. We conducted a nationwide, population-based, retrospective cohort study, using the French National Hospital Discharge Database (PMSI), to describe BoNT-A use for spasticity in clinical practice in France between 2014 and 2020. The PMSI database covers the whole French population, corresponding to over 66 million persons.
    Methods: We first searched the PMSI database for healthcare facility discharge of patients who received BoNT-A injections between 2014 and 2020, corresponding to the first set. For each BoNT-A-treated patient, we identified the medical condition for which BoNT-A may have been indicated. Another search of the PMSI database focused on patients admitted for acute stroke between 2014 and 2016 and their spasticity-related care pathway (second set). Overall, two subpopulations were analysed: 138,481 patients who received BoNT-A injections between 2014 and 2020, and 318,025 patients who survived a stroke event between 2014 and 2016 and were followed up until 2020.
    Results: Among the 138,481 BoNT-A-treated patients, 53.5% received only one or two BoNT-A injections. Most of these patients (
    Conclusion: Our analysis of the exhaustive PMSI database showed a suboptimal implementation of BoNT-A treatment recommendations in France. BoNT-A treatment initiation and re-administration are low, particularly in patients with post-stroke spasticity. Further investigations may help explain this observation, and may target specific actions to improve spasticity-related care pathway.
    Language English
    Publishing date 2023-08-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2023.1245228
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies.

    Seddiki, Nabila / Lévy, Yves

    Current opinion in HIV and AIDS

    2018  Volume 13, Issue 2, Page(s) 119–127

    Abstract: Purpose of review: The purpose is to recall some of the key immunological elements that are at the crossroad and need to be combined for developing a potent therapeutic HIV-1 vaccine.: Recent findings: Therapeutic vaccines and cytokines have been ... ...

    Abstract Purpose of review: The purpose is to recall some of the key immunological elements that are at the crossroad and need to be combined for developing a potent therapeutic HIV-1 vaccine.
    Recent findings: Therapeutic vaccines and cytokines have been commonly used to enhance and/or recall preexisting HIV-1 specific cell-mediated immune responses aiming to suppress virus replication. While the vaccine is important to stimulate HIV-1 specific T-cell responses, the cytokine may support the expansion of the stimulated virus-specific T cells. Moreover, the current success of immune checkpoint blockers in cancer therapy render them very attractive to use in HIV-1 infected individuals, with the objective to preserve the function of HIV-specific T cells from exhaustion and target directly HIV-1 cell reservoir. More recently, the development of passive immunotherapy using broad neutralizing HIV antibodies (bNAbs) and their potential capacity to elicit innate or adaptive HIV-cellular responses, beyond their neutralizing activity, offers a new opportunity to improve the efficiency of therapeutic vaccine. These major advances provide the scientific basis for developing potent combinatorial interventions in HIV-1 infected patients.
    Summary: Major advances in our immunological understanding resulting from basic science and clinical trials studies have paved the way and established a solid platform to jump over the stumbling blocks that prevent the field from developing a therapeutic HIV-1 vaccine. It is time for immuno-modulation and combinatorial strategies towards HIV-1 eradication.
    MeSH term(s) AIDS Vaccines/administration & dosage ; AIDS Vaccines/genetics ; AIDS Vaccines/immunology ; Animals ; HIV Antibodies/immunology ; HIV Infections/genetics ; HIV Infections/immunology ; HIV Infections/prevention & control ; HIV Infections/virology ; HIV-1/genetics ; HIV-1/immunology ; Humans ; Immunomodulation ; T-Lymphocytes/immunology ; T-Lymphocytes/virology
    Chemical Substances AIDS Vaccines ; HIV Antibodies
    Language English
    Publishing date 2018-01-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2502511-9
    ISSN 1746-6318 ; 1746-630X
    ISSN (online) 1746-6318
    ISSN 1746-630X
    DOI 10.1097/COH.0000000000000444
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Perpetuation of vaccine memory T cell responses against SIV/HIV.

    Lévy, Yves

    EMBO molecular medicine

    2011  Volume 3, Issue 9, Page(s) 507–509

    MeSH term(s) AIDS Vaccines/immunology ; Animals ; HIV/immunology ; Humans ; Immunologic Memory ; Macaca mulatta ; Simian Acquired Immunodeficiency Syndrome/immunology ; Simian Acquired Immunodeficiency Syndrome/prevention & control ; Simian Immunodeficiency Virus/immunology ; T-Lymphocytes/immunology ; Vaccines, Synthetic/immunology
    Chemical Substances AIDS Vaccines ; Vaccines, Synthetic
    Language English
    Publishing date 2011-08-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 2467145-9
    ISSN 1757-4684 ; 1757-4676
    ISSN (online) 1757-4684
    ISSN 1757-4676
    DOI 10.1002/emmm.201100163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Reply to Bordoni et al.

    Thiébaut, Rodolphe / Lévy, Yves

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2016  Volume 63, Issue 12, Page(s) 1684–1685

    Language English
    Publishing date 2016--15
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciw642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top